Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.53
AFFX's Cash to Debt is ranked higher than
57% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. AFFX: 0.53 )
AFFX' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.53

Equity to Asset 0.56
AFFX's Equity to Asset is ranked higher than
68% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. AFFX: 0.56 )
AFFX' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.95
Current: 0.56

0.19
0.95
F-Score: 8
Z-Score: 1.53
M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -0.08
AFFX's Operating margin (%) is ranked higher than
72% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. AFFX: -0.08 )
AFFX' s 10-Year Operating margin (%) Range
Min: -254.35   Max: 17.26
Current: -0.08

-254.35
17.26
Net-margin (%) 0.11
AFFX's Net-margin (%) is ranked higher than
74% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. AFFX: 0.11 )
AFFX' s 10-Year Net-margin (%) Range
Min: -232.61   Max: 17.9
Current: 0.11

-232.61
17.9
ROE (%) 0.14
AFFX's ROE (%) is ranked higher than
73% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. AFFX: 0.14 )
AFFX' s 10-Year ROE (%) Range
Min: -68.27   Max: 22.99
Current: 0.14

-68.27
22.99
ROA (%) 0.08
AFFX's ROA (%) is ranked higher than
75% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. AFFX: 0.08 )
AFFX' s 10-Year ROA (%) Range
Min: -33.34   Max: 10.32
Current: 0.08

-33.34
10.32
ROC (Joel Greenblatt) (%) -0.39
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. AFFX: -0.39 )
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -128.18   Max: 80.9
Current: -0.39

-128.18
80.9
Revenue Growth (%) 0.80
AFFX's Revenue Growth (%) is ranked higher than
68% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. AFFX: 0.80 )
AFFX' s 10-Year Revenue Growth (%) Range
Min: -33.6   Max: 102.9
Current: 0.8

-33.6
102.9
EPS Growth (%) 15.30
AFFX's EPS Growth (%) is ranked higher than
88% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. AFFX: 15.30 )
AFFX' s 10-Year EPS Growth (%) Range
Min: -55.3   Max: 25.1
Current: 15.3

-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AFFX Guru Trades in Q4 2013

Jim Simons 1,032,500 sh (+151.58%)
PRIMECAP Management 10,666,640 sh (+31.13%)
Paul Tudor Jones 48,674 sh (+3.12%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 130,000 sh (-13.33%)
Joel Greenblatt 31,187 sh (-88.37%)
» More
Q1 2014

AFFX Guru Trades in Q1 2014

Joel Greenblatt 151,285 sh (+385.09%)
Paul Tudor Jones 56,400 sh (+15.87%)
PRIMECAP Management 10,690,540 sh (+0.22%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 769,223 sh (-25.5%)
Chuck Royce 90,000 sh (-30.77%)
» More
Q2 2014

AFFX Guru Trades in Q2 2014

Chuck Royce 90,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (-1.23%)
Joel Greenblatt 72,552 sh (-52.04%)
Paul Tudor Jones 20,400 sh (-63.83%)
Jim Simons 198,280 sh (-74.22%)
» More
Q3 2014

AFFX Guru Trades in Q3 2014

Jim Simons 576,885 sh (+190.94%)
Paul Tudor Jones 29,500 sh (+44.61%)
PRIMECAP Management 10,559,240 sh (unchged)
Chuck Royce 90,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$7.98 - $9.36 $ 9.4210%0
Joel Greenblatt 2014-06-30 Reduce -52.04%0.01%$6.37 - $9.419 $ 9.4219%72552
Joel Greenblatt 2014-03-31 Add 385.09%0.01%$6.65 - $9.5 $ 9.4216%151285
Joel Greenblatt 2013-12-31 Reduce -88.37%0.05%$6.35 - $8.85 $ 9.4223%31187
PRIMECAP Management 2013-12-31 Add 31.13%0.03%$6.35 - $8.85 $ 9.4223%10666640
Joel Greenblatt 2013-09-30 New Buy0.05%$3.78 - $6.3 $ 9.4283%268084
PRIMECAP Management 2013-09-30 Add 22.94%0.01%$3.78 - $6.3 $ 9.4283%8134440
Joel Greenblatt 2012-09-30 Sold Out 0.06%$3.61 - $4.7 $ 9.42126%0
Joel Greenblatt 2012-06-30 Reduce -50.63%0.07%$4.01 - $5.11 $ 9.42105%175755
PRIMECAP Management 2012-06-30 Add 149.79%0.03%$4.01 - $5.11 $ 9.42105%7025440
Joel Greenblatt 2012-03-31 Add 67.73%0.05%$4.11 - $5.21 $ 9.42125%356011
Joel Greenblatt 2011-12-31 Add 92.44%0.05%$3.7 - $5.83 $ 9.4297%212251
Joel Greenblatt 2011-09-30 New Buy0.09%$4.14 - $8 $ 9.4268%110294
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 942.00
AFFX's P/E(ttm) is ranked higher than
77% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: 942.00 )
AFFX' s 10-Year P/E(ttm) Range
Min: 11.36   Max: 971
Current: 942

11.36
971
P/B 2.60
AFFX's P/B is ranked higher than
83% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. AFFX: 2.60 )
AFFX' s 10-Year P/B Range
Min: 0.24   Max: 12.23
Current: 2.6

0.24
12.23
P/S 2.00
AFFX's P/S is ranked higher than
82% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. AFFX: 2.00 )
AFFX' s 10-Year P/S Range
Min: 0.38   Max: 11.22
Current: 2

0.38
11.22
PFCF 15.70
AFFX's PFCF is ranked higher than
96% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: 15.70 )
AFFX' s 10-Year PFCF Range
Min: 1.89   Max: 1220.5
Current: 15.7

1.89
1220.5
EV-to-EBIT -2692.22
AFFX's EV-to-EBIT is ranked higher than
69% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: -2692.22 )
AFFX' s 10-Year EV-to-EBIT Range
Min: -2863   Max: 670
Current: -2692.22

-2863
670
Current Ratio 2.73
AFFX's Current Ratio is ranked higher than
73% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. AFFX: 2.73 )
AFFX' s 10-Year Current Ratio Range
Min: 1.52   Max: 23.52
Current: 2.73

1.52
23.52
Quick Ratio 1.93
AFFX's Quick Ratio is ranked higher than
68% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. AFFX: 1.93 )
AFFX' s 10-Year Quick Ratio Range
Min: 1.25   Max: 23.21
Current: 1.93

1.25
23.21

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.76
AFFX's Price/DCF (Projected) is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: 1.76 )
AFFX' s 10-Year Price/DCF (Projected) Range
Min: 0.42   Max: 219.36
Current: 1.76

0.42
219.36
Price/Median PS Value 1.13
AFFX's Price/Median PS Value is ranked higher than
78% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. AFFX: 1.13 )
AFFX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 38.33
Current: 1.13

0.31
38.33
Forward Rate of Return (Yacktman) -7.17
AFFX's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. AFFX: -7.17 )
AFFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.7   Max: 12.2
Current: -7.17

-19.7
12.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 08 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Affymetrix Reports Fourth Quarter and Fiscal Year 2008 Results Jan 28 2009 
Affymetrix to Host Conference Call on January 28, 2009 to Announce Fourth Quarter and Fiscal 2008 Re Jan 27 2009 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 


More From Other Websites
Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session Dec 15 2014
Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% Dec 12 2014
Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4% Dec 10 2014
Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session Dec 10 2014
eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA and Protein... Dec 09 2014
eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA and Protein... Dec 09 2014
Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% Dec 08 2014
Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher Dec 08 2014
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% Dec 08 2014
uniQure N.V. (QURE) Jumps: Stock Adds 6.3% in Session Dec 08 2014
Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% Dec 05 2014
Affymetrix, Binding Site Group Ink Distribution Deal Dec 04 2014
Merge Healthcare (MRGE) Worth Watching: Stock Gains 6.5% Dec 04 2014
ADMA Biologics Slumps: ADMA Tanks 11% in Session Dec 04 2014
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% Dec 04 2014
The Binding Site and eBioscience, an Affymetrix Business, Partner in Clinical Flow Cytometry Reagent... Dec 03 2014
Biogen Idec (BIIB) Shows Strength: Stock Moves 6.4% Up Dec 03 2014
The Binding Site and eBioscience, an Affymetrix Business, Partner in Clinical Flow Cytometry Reagent... Dec 03 2014
ImmunoCellular Therapeutics (IMUC) Soars: Stock Rises 40.9% Dec 03 2014
Can Affymetrix (AFFX) Keep the Earnings Streak Alive This Quarter? Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK